ALK and lung cancer: Therefore, molecular tests are routinely performed to identify mutations in oncogenes in lung cancer, including EGFR and ALK; to identify those patients with a high likelihood of response to targeted therapy; and reduce unnecessary side effects of ineffective treatments.